29P Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results M. Tiseo, S. Popat, H. R. Kim,M-J. Ahn,J. C. Yang,J-Y. Han,M. J. Hochmair,K. H. Lee, A. Delmonte,M. R. Garcia Campelo,D-W. Kim, F. Griesinger, E. Felip,R. Califano, A. I. Spira, S. N. Gettinger,H. M. Lin,Y. Liu, F. Vranceanu, R. CamidgeAnnals of Oncology（2022）引用 0|浏览8暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
